Trials / Completed
CompletedNCT00911092
Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer
Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Centre Oscar Lambret · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.
Detailed description
Further informations will be provided by Centre Oscar Lambret.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood sampling | Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy |
| RADIATION | Radiation | Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks |
| DRUG | Chemotherapy (Fluorouracil and Cisplatin) | At weeks 1, 5, 8 and 11 * Day 1 to day 4: Fluorouracil 1 gr/m²/day * Day 1 or 2: Cisplatin 75 mg/m² |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2011-09-01
- Completion
- 2011-12-01
- First posted
- 2009-06-01
- Last updated
- 2012-01-02
Locations
6 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00911092. Inclusion in this directory is not an endorsement.